Oramed Pharmaceuticals INC Form 4 insider transactions

Joshua Hexter, COO & CBO of Oramed Pharmaceuticals, reported transactions involving the sale of common stock and the exercise of stock options.

Oramed Pharmaceuticals CFO Avraham Gabay sold 73,360 shares of common stock on July 1, 2026, pursuant to a Rule 10b5-1 trading plan.

Oramed Pharmaceuticals CEO Nadav Kidron disposed of 44,818 shares of common stock to cover tax withholding obligations related to RSU vesting.

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, disposed of 435,084 shares of common stock to cover tax withholding obligations related to RSU vesting.

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, received a grant of 119,558 Restricted Stock Units, vesting quarterly starting April 2026.

Oramed Pharmaceuticals Inc. CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units, which will vest quarterly starting April 1, 2026.

ORAMED PHARMACEUTICALS INC. COO & CBO Joshua Hexter reported the acquisition of 95,889 Restricted Stock Units, vesting quarterly starting April 1, 2026.

Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay was granted 95,889 Restricted Stock Units, vesting quarterly starting April 1, 2026.

Oramed Pharmaceuticals Inc. President and CEO Nadav Kidron reported a charitable donation of 100,000 common shares.

Oramed Pharmaceuticals' COO and CBO, Joshua Hexter, acquired 19,000 shares of common stock through the vesting of performance stock units.

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, converted 19,000 performance stock units into common stock following the achievement of a specified share price.

Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay acquired 19,000 shares of common stock through the vesting of performance stock units.

Oramed Pharmaceuticals CEO Nadav Kidron acquired 109,000 common shares following the vesting of performance stock units tied to a specific stock price achievement.

Miriam Kidron, Chief Scientific Officer and Director of Oramed Pharmaceuticals Inc., reported a charitable donation of 86,166 shares of common stock.

Oramed Pharmaceuticals Director Yehuda Reznick received grants of 36,250 Restricted Stock Units, vesting over future periods.

Oramed Pharmaceuticals CEO Nadav Kidron acquired significant equity awards, including Restricted Stock Units and Performance Stock Units, aligning his interests with long-term company performance.

Oramed Pharmaceuticals Chief Scientific Officer Miriam Kidron reported the acquisition of Restricted Stock Units and Performance Stock Units.

Oramed Pharmaceuticals COO & CBO Joshua Hexter reported the acquisition of over 200,000 Restricted Stock Units and 19,000 Performance Stock Units.

Oramed Pharmaceuticals Director Benjamin Shapiro reported the acquisition of 33,500 Restricted Stock Units, set to vest over future periods.

Oramed Pharmaceuticals Director Arie Mayer received two grants of Restricted Stock Units totaling 34,900 shares, increasing his beneficial ownership.

Oramed Pharmaceuticals Director Daniel Aghion acquired 36,250 Restricted Stock Units, increasing his direct beneficial ownership to 113,441 shares.

Oramed Pharmaceuticals' CFO Avraham Gabay reported significant equity awards, including Restricted Stock Units and Performance Stock Units, increasing his beneficial ownership.

Oramed Pharmaceuticals Inc. Director Arie Mayer reported the acquisition of 36,975 Restricted Stock Units (RSUs) in a recent SEC Form 4 filing, increasing his direct beneficial ownership to 133,109 common shares.

Oramed Pharmaceuticals Inc. director Daniel Aghion was granted 38,371 Restricted Stock Units (RSUs) on June 5, 2025, aligning his interests with shareholders through future equity vesting.

Oramed Pharmaceuticals Inc. Director Yehuda Reznick reported the acquisition of 38,370 Restricted Stock Units (RSUs) on June 5, 2025, increasing his direct beneficial ownership to 68,930 shares.

Oramed Pharmaceuticals Inc. Director Leonard Sank reported the acquisition of 36,510 Restricted Stock Units (RSUs) on June 5, 2025, increasing his direct beneficial ownership to 134,531 shares of common stock.

Oramed Pharmaceuticals Director and 10% owner Benjamin Shapiro has increased his beneficial ownership in the company through the acquisition of 34,650 Restricted Stock Units (RSUs) on June 5, 2025.

Miriam Kidron, Chief Scientific Officer of Oramed Pharmaceuticals, reports the acquisition of common stock through the settlement of performance stock units (PSUs).

Joshua Hexter, COO & CBO of Oramed Pharmaceuticals, reports the acquisition of common stock following the settlement of performance stock units (PSUs).

Nadav Kidron, CEO of Oramed Pharmaceuticals, acquired a total of 427,000 shares of common stock on February 11, 2025, through the vesting of performance stock units (PSUs).